- 1 Recommendations for surveillance of pulmonary dysfunction
- among childhood, adolescent, and young adult cancer survivors: a
  - report from the International Late Effects of Childhood Cancer
- **4 Guideline Harmonization Group**
- 6 Maria Otth MD\*, Rahel Kasteler MD\*, Renée L. Mulder PhD, Jennifer Agrusa MD, Saro H.
- 7 Armenian DO, Dana Barnea MD, Prof Anne Bergeron MD, Neel S. Bhatt MD, Stephen J. Bourke
- 8 MD, Prof Louis S. Constine MD, Myrofora Goutaki PhD, Prof Daniel M. Green MD, Ulrike
- 9 Hennewig MD, Veronique Houdouin MD, Prof Melissa M. Hudson MD, Prof Leontien Kremer PhD,
- 10 Prof Philipp Latzin MD, Antony Ng PhD, Kevin C. Oeffinger MD, Christina Schindera MD, Prof
- 11 Roderick Skinner PhD, Grit Sommer PhD, Saumini Srinivasan MD, Dennis C. Stokes MD, Birgitta
- 12 Versluys MD, Nicolas Waespe MD, Daniel J. Weiner MD, Andrew C. Dietz MD°, Prof Claudia E.
- 13 Kuehni MD°

5

16 17 18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37 38

39

40

41

42

43

44

45

46

47

- 14 \*shared first authors
- 15 °shared last authors
  - Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland (M Goutaki PhD, C Schindera MD, G Sommer PhD, N Waespe MD, Prof CE Kuehni MD)
  - Department of Oncology, Haematology, Immunology, Stem Cell Transplantation and Somatic Gene Therapy, University Children's Hospital Zurich, Zurich, Switzerland (M Otth MD, R Kasteler MD)
  - Pediatric Hematology-Oncology Center, Children's Hospital of Eastern Switzerland, St Gallen, Switzerland (M Otth MD, R Kasteler MD)
  - Department of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland (M Otth MD)
  - Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands (RL Mulder PhD, Prof LCM Kremer PhD, B Versluys MD)
  - Department of Pediatric Hematology Oncology, C.S. Mott Children's Hospital, University of Michigan, Michigan, USA (J Agrusa MD)
  - Department of Pediatrics, City of Hope, Duarte, California, USA (SH Armenian MD)
  - Department of Hematology and Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (D Barnea MD)
    - Hôpitaux Universitaires de Genève, Université de Genève, Genève, Switzerland (Prof A Bergeron MD)
      - Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA (NS Bhatt MD)
      - Department of Respiratory Medicine, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom (SJ Bourke MD)
      - Departments of Radiation Oncology and Pediatrics, University of Rochester Medical Center, Rochester, NY, USA (Prof LS Constine MD)
  - Department of Oncology (Prof MM Hudson MD, Prof DM Green MD), Department of Epidemiology and Cancer Control (Prof MM Hudson MD), St Jude Children's Research Hospital, Memphis, TN, USA
    - University Hospital of Giessen and Marburg, Pediatric Hematology and Oncology, Giessen, Germany (U Hennewig MD)
    - AP-HP, Hôpital Robert Debré, Service de Pneumopédiatrie, Paris, France (V Houdouin MD)

- Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics,
   Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland (M Goutaki PhD,
   Prof P Latzin MD)
  - Department of Paediatric Oncology, Royal Hospital for Children, Bristol, UK (A Ng PhD)
  - Department of Community and Family Medicine, Duke University School of Medicine, Durham, NC, USA (KC Oeffinger MD)
    - Division of Pediatric Oncology/Haematology, University Children's Hospital Basel, University of Basel, Basel, Switzerland (C Schindera MD)
    - Department of Paediatric and Adolescent Haematology/ Oncology, Great North Children's Hospital and Newcastle University Centre for Cancer, Newcastle upon Tyne, UK (Prof R Skinner PhD)
    - Division of Pulmonology, Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, USA (S Srinivasan MD, D Stokes MD)
    - Pediatric Hematology and Oncology, University Children's Hospital Bern, University of Bern, Bern, Switzerland (N Waespe MD, Prof. CE Kuehni MD)
    - CANSEARCH Research Platform for Paediatric Oncology and Haematology, Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland (N Waespe MD)
    - Division of Pediatric Pulmonology, University of Pittsburgh, Pittsburgh, PA, USA (DJ Weiner MD)
    - Shape Therapeutics, Inc., Seattle, WA, USA (AC Dietz MD)

# **Corresponding author:**

 Claudia E Kuehni
Institute of Social and Preventive Medicine
University of Bern
Bern, Switzerland
claudia.kuehni@unibe.ch
Phone: 0041 31 684 35 07

# **Source of support:**

Swiss Cancer Research (grant no: KFS-4157-02-2017, KLS/KFS-4825-01-2019 and KFS-5302-02-2021), Cancer League Bern, Kinderkrebshilfe Schweiz and Lung League Bern supported our study.

# **Keywords:**

- Children
- Adolescents
- Young adults
- Survivors
- Childhood cancer/malignancy
- Late effects
- Pulmonary dysfunction
  - Lung disease
- Respiratory
- Surveillance
- 97 Lung Function

101	ATS	American Thoracic Society
102	CAYA	Childhood Adolescent and Young Adult
103	COG	Childrens' Oncology Group
104	DCOG	Dutch Childrens' Oncology Group
105	DLCO	Diffusion capacity for carbon-monoxide
106	ERS	European Respiratory Society
107	FEV1	Forced expiratory volume in the first second
108	FVC	Forced vital capacity
109	GLI	Global Lung Initiative
110	GRADE	Grading of Recommendations, Assessment, Development and Evaluation
111	GvHD	Graft versus Host Disease
112	HSCT	Haematopoietic Stem Cell Transplantation
113	IGHG	International Guideline Harmonization Group

114 LTFU Long-term follow-up

100

**Abbreviations** 

115 MEF25-75% Maximal expiratory flow between 25% and 75% of the FVC

116 PFT Pulmonary function testing

PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses

118RVResidual volume119TBITotal Body Irradiation120TLCTotal lung capacity

121 UKCCLG United Kingdom Children's Cancer and Leukaemia Group

# **ABSTRACT**

Childhood, adolescent, and young adult (CAYA) cancer survivors are at risk of pulmonary dysfunction. Current follow-up care guidelines are discordant. Therefore, the International Late Effects of Childhood Cancer Guideline Harmonization Group established and convened a panel of 33 experts to develop evidence-based surveillance guidelines. We critically reviewed available evidence regarding risk factors for pulmonary dysfunction, types of pulmonary function testing, and timings of surveillance, then we formulated our recommendations. We recommend that CAYA cancer survivors and healthcare providers are aware of reduced pulmonary function risks and pay vigilant attention to potential symptoms of pulmonary dysfunction, especially among survivors treated with allogeneic haematopoietic stem cell transplantation, thoracic radiotherapy, and thoracic surgery. Based on existing limited evidence, our panel currently recommends pulmonary function testing only for symptomatic survivors. Since scarce existing evidence informs our recommendation, we highlight the need for prospective collaborative studies to address pulmonary function knowledge gaps among CAYA cancer survivors.

## INTRODUCTION

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

Children, adolescents, and young adults (CAYA) diagnosed with cancer are at risk for pulmonary dysfunction and death from pulmonary conditions years to decades after completing treatment (1-5). Treatment modalities previously defined as lung-toxic include chemotherapeutic agents, such as busulfan, bleomycin, carmustine, and lomustine, and thoracic radiotherapy, thoracic surgery, and allogeneic haematopoietic stem cell transplantation (HSCT) (6, 7). Pathophysiological mechanisms of pulmonary damage include oxidative stress from lung-toxic chemotherapeutics, free radical formation during radiotherapy, and transplant-specific pulmonary complications, such as idiopathic pneumonia syndrome or bronchiolitis obliterans (7-9). Free radicals injure type II pneumocytes, resulting in decreased proliferative capacity, less surfactant production, and ultimately reduced lung compliance (10). Activations of an inflammatory cascade and changes in endothelial cells of surrounding vasculature result in leakage of proteins and inflammatory cells into alveoli (10). Such inflammation is commonly the final path of different pathophysiological mechanisms which can either resolve or progress to fibrotic changes in alveolar septa, causing restrictive impairments. Surgical removal of parts of the lung or chest wall as part of cancer therapy reduces lung volumes and causes restrictive changes. Symptomatic pulmonary dysfunction presents with chronic cough or dyspnea, especially on exertion. With large pulmonary functional reserve, dyspnea may not be noticed until a substantial decline in pulmonary function has occurred. Pulmonary function testing (PFT) detects pulmonary dysfunction before symptoms arise. Commonly used PFT include spirometry, body plethysmography, and measurement of diffusion capacity for carbon-monoxide (DLCO). Spirometry and body plethysmography mainly assess changes in larger airways. Examinations detecting changes in lung periphery or inhomogeneous ventilation, such as washout tests, are used to answer research questions, yet remain unintroduced into routine clinical care (11). Among CAYA cancer survivors exposed to lung-toxic treatments, obstructive changes have been reported in up to 4%, restrictive disease 24%, and diffusion capacity impairment 49% (1, 2). Proportions are even higher among certain sub-groups of CAYA cancer survivors, such as following HSCT (12).

Since long-term CAYA cancer survivor numbers constantly increase from diagnostic, risk stratification, and treatment strategy advances, long-term CAYA cancer survivor surveillance is a high priority (13). Awareness of the risk of late effects from cancers or treatments led to the development of different long-term follow-up (LTFU) guidelines, such as those from the Children's Oncology Group (COG), the Dutch Childhood Oncology Group (DCOG), and from the United Kingdom Children's Cancer and Leukaemia Group (UKCCLG) (14-16). Although COG, DCOG, and UKCCLG guidelines recommend screening for pulmonary dysfunction, they are discordant regarding indication, timing of initiation, frequency, and screening method. The International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) surveillance guidelines develop internationally harmonised and implementable recommendations based on evidence from existing literature and international expert consensus when evidence is unavailable (17). In this current IGHG initiative, we specifically define which CAYA cancer survivors likely benefit from screening for pulmonary dysfunction and when and how screening should be performed. We also further highlight limitations of the current evidence informing surveillance recommendations for pulmonary dysfunction and knowledge gaps to address in future research.

# **METHODS**

Methodology of International Late Effects of Childhood Cancer Guideline Harmonization

Group (IGHG) and formulating key questions

181 Information about methods used to formulate IGHG recommendations was published previously (18).

For our current recommendation, we organised a guideline panel of 33 members—representing COG,

DCOG, UKCCLG, the Pan-European Network for Care of Survivors after Childhood and Adolescent

Cancer (PanCare)—and pulmonary health and late effects experts from various medical specialties:

paediatric oncology and haematology; paediatric and adult pulmonology; radiation oncology;

epidemiology; and guideline experts (Appendix A) (19-21).

IGHG's approach to formulating recommendations involves answering five key questions: 1) "Who

needs surveillance?" 2) "What surveillance modality should be used?" 3) "At what frequency should

surveillance be performed?" 4) "When should surveillance be initiated?" and 5) "What should be done

when abnormalities are found?" Based on our preliminary literature search and a resulting absence of

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

data, we performed the systematic literature search for only question 1) "Who needs surveillance?" and used expert opinions from paediatric and adult pulmonologists for questions 2–5. We did not use guidelines for surveillance of other pulmonary diseases, such as idiopathic interstitial pneumonitis or chronic obstructive pulmonary disease, due to different underlying pathophysiological mechanisms. Notably, guidelines for other diseases start with symptomatic patients diagnosed with specific pulmonary diseases, which differs from our population of interest—asymptomatic CAYA cancer survivors at risk of developing pulmonary problems. Comparing existing guidelines and formulating clinical questions First, we separately compared COG, DCOG, Scottish Intercollegiate Guidelines Network, and UKCCLG recommendations for each of the five key questions (15, 16, 19, 22). For the key question, "What should be done when abnormalities are found?" we also included vaccination and lifestyle factors. For the key question "Who needs surveillance?" we subsequently formulated 11 clinical questions and sub-questions to strengthen concordant recommendations and find consensus for discordant recommendations (Appendix B). We used the PICO-framework to formulate clinical questions (23). Our population of interest included CAYA cancer survivors—defined by at least 50% of survivors diagnosed before age 30—who completed cancer treatment at least two years previously. We included potentially lung-toxic treatment modalities (selected chemotherapeutic agents, thoracic radiotherapy, thoracic surgery, and allogeneic HSCT) and tobacco exposure as interventions. We also included all chemotherapeutic agents mentioned in current LTFU guidelines as risk factors for pulmonary dysfunction (bleomycin, busulfan, and nitrosoureas [lomustine and carmustine]). Based on expert opinion, we additionally included treatment with cyclophosphamide, gemcitabine, and methotrexate. Comparators were considered during data extraction and differed between studies according to study design, such as non-exposed survivors, survivors exposed to lower chemotherapeutic doses, or community controls. Our outcome of interest was pulmonary dysfunction assessed by PFT. We focused on this single outcome because our preliminary literature search showed that other commonly reported clinical endpoints—in particular survivor-reported symptoms or clinician-reported diagnoses—had been assessed and reported heterogeneously and had the risk of subjectivity, such as different definitions of chronic

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

cough or dyspnea (24-28). We categorised pulmonary dysfunction into four groups: obstruction (by FEV1, FEV1/FVC, MEF25–75%); restriction (by TLC, FVC); hyperinflation (by RV, RV/TLC); and diffusion capacity impairment (by DLCO). Although clinically relevant hyperinflation should be interpreted together with obstruction, we defined hyperinflation as a separate pulmonary outcome since it was defined as such in included studies. Systematic literature search on "Who needs surveillance?" We conducted our first systematic literature search in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines restricted to PubMed and Ovid in November 2016 with updates in June 2019; December 2020; June 2022; and April 2023 (29). We developed our search strategy based on 11 clinical questions and five concepts: cancer diagnosis, population of CAYA cancer survivors, potential lung-toxic treatment modalities, pulmonary outcomes, and late effects (Appendix C). The inclusion criteria were given through the PICOframework. We also excluded studies with fewer than 20 participants and studies only assessing prevalence of pulmonary dysfunction without measuring effect sizes of associations between exposures and pulmonary dysfunction (Appendix D). Guideline panel members screened titles, abstracts, and full-texts. Two authors independently screened each study. Coordinators (MO, RK) resolved discrepancies. We extracted data from each study and entered it into evidence summary tables (Appendix E); separately performed risk of bias assessments for each study (Appendix F); and completed overall quality assessments of available evidence for each clinical question, according to the GRADE criteria (Appendix G) (18, 30). Each eligible study could contribute to answering more than one clinical question. For our overall conclusion of evidence, we summarised findings by type of pulmonary dysfunction (Appendix H). Expert consensus on surveillance modality, start and frequency of screening, and procedures in case of pulmonary dysfunction For questions about surveillance modality, start and frequency of screening, and procedures in cases of pulmonary dysfunction (key questions  $2 \square 5$ ), we held numerous meetings with paediatric and adult pulmonologists and guideline development experts. We formulated suggestions based on initial meetings, which we then discussed with guideline panel members until reaching consensus through an iterative approach with successive revisions and implementing suggestions from all panel members.

# **Translating evidence into recommendations**

We assessed evidence and information we gathered from our systematic literature search and expert consensus within the evidence-to-decision framework—it weighs the impact of screening by estimating benefits and harms, resources and costs, impact on health inequities, acceptability, and feasibility. Through panel discussions, we achieved consensus for final recommendations, which we subsequently discussed with additional experts, including oncologists and survivors (Appendix A).

## **RESULTS**

# **Comparison with existing guidelines**

Comparing existing guidelines revealed relevant discordance (Appendix I). Since the Scottish guideline omitted recommendations for pulmonary dysfunction, we excluded it (22). The remaining three guidelines considered CAYA cancer survivors at risk for pulmonary dysfunction after exposure to bleomycin, busulfan, nitrosoureas, thoracic radiotherapy, or thoracic surgery. Practical details revealed discordances, including cut-off doses for chemotherapeutic agents or thoracic radiotherapy; radiation volume; age at treatment; and additional risk factors, such as renal dysfunction and pulmonary infection. All three guidelines recommended PFT, yet did not specify tests. We found no concordance for screening frequency and starting screening with five and ten years after diagnosis in the Dutch guideline; two years after completion of treatment in the COG guideline; and end of treatment in the UK guideline. Guidelines agreed about referring CAYA cancer survivors to pulmonologists in cases of pulmonary dysfunction; alerting anaesthetists about previous bleomycin treatment; advising survivors not to smoke; and considering pneumococcal and influenza immunisation (Appendix I).

# General results from systematic literature search

Our systematic literature search identified 9284 studies. We assessed 704 full-texts for eligibility; 26 studies fulfilled inclusion criteria (Figure 1, Table 1) (1-3, 31-53). Reasons for excluding full-texts mainly included 1) assessing outcomes other than pulmonary function by PFT (n=186); 2) including

non-CAYA cancer survivors (n=164); and 3) assessing outcomes fewer than two years after completing treatment (n=91). Most studies (n=12) included CAYA survivors of different cancer types; followed by studies on leukaemia (n=7), lymphoma (n=4), and brain tumors, neuroblastoma, and osteosarcoma with one study each. Appendix J contains key characteristics and our summary of evidence for each included study; Appendix K presents our evidence assessment summary and quality of data contributing to recommendations per clinical question. Quality of evidence was very low or low for most clinical questions (Table 2). We summarise primary reasons for downgrading the quality of evidence in Table 3 and provide more detail in Appendix K.

#### Evidence on risk factors for pulmonary dysfunction among CAYA cancer survivors

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

We identified seven studies examining allogeneic HSCT as a risk factor for pulmonary dysfunction (31-37); 13 studies for thoracic radiotherapy (1-3, 31, 38, 40, 45-48, 50-52); five studies for thoracic surgery (1, 31, 38-40); between one and eight studies for selected chemotherapeutic agents (bleomycin, busulfan, nitrosoureas, cyclophosphamide, methotrexate); no studies for gemcitabine; and six studies for tobacco exposure (2, 40, 41, 43-45) (Table 2, Appendix K). For busulfan and nitrosoureas, only one study of very low quality was available; it provided insufficient evidence to decide whether these agents significantly impact pulmonary function (2). Four studies of low to very low quality of evidence assessed pulmonary function after cyclophosphamide-containing treatment (1, 42, 46, 47). Studies examining effects from active tobacco smoking showed contradictory results (2, 41, 43-45). No studies examined impact from passive tobacco smoking or cannabis use. Our clinical questions and sub-questions aimed to investigate impact from exposure versus non-exposure and also impact from different dose levels; age at exposure; chronic graft versus host disease; infections; and total body irradiation among individuals treated with HSCT (Appendix B). Between one and four studies examined impact from different cyclophosphamide, methotrexate, and bleomycin doses; yet no studies were available for different doses of nitrosoureas and busulfan. Seven studies examined the impact of age at treatment with HSCT and radiotherapy. Overall, we identified several potential sources of bias and methodological issues in most studies (Table 3). Study design was retrospective in more than half (n=14), increasing risks of bias and nonstandardised measurements. Half of the studies did not describe original population sizes from where they selected participants at risk. This makes it uncertain if results are internally and externally representative and can be extrapolated for the entire population of CAYA cancer survivors. Only half of the studies described how they performed pulmonary function testing, such as by implementing the joint European Respiratory Society (ERS)-American Thoracic Society (ATS) recommendations. Even though most studies (74%) reported reference values used to standardize CAYA cancer survivor PFT results, studies used 22 different sources of reference values—with up to ten different sources in one study (47). Only two studies used internationally recommended all-age reference values from the Global Lung Initiative (GLI) (3, 52). Cut-off value definitions, such as for restrictive disease, were inconsistent, which made PFT results difficult to interpret and impossible to compare between studies and age groups. Additionally, findings from different studies on the same exposure were frequently inconsistent or contradictory, such as with bleomycin (31, 38, 39). Inconsistent and contradictory aspects precluded analysing quantitatively and interpreting findings, such as a meta-analysis; prevented formulation of recommendations for specific pulmonary function abnormalities, such as obstructive, restrictive, and diffusion impairment; confounded analysis of effects of specific chemotherapeutic agents on pulmonary function; or prevented definition of cut-off doses for chemotherapeutics or radiotherapy. However, studies we examined provided some evidence CAYA cancer survivors treated with allogeneic HSCT, thoracic radiotherapy, and thoracic surgery are at risk for pulmonary dysfunction as measured by PFT.

#### Translating evidence and expert consensus into recommendations

Asymptomatic CAYA cancer survivors

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

Our panel concluded evidence was insufficient for recommending routine PFT for asymptomatic CAYA cancer survivors at present (Appendix L, Table 4). The current evidence is low quality with risks of participation bias and cannot be translated to represent the wider general situation in asymptomatic CAYA cancer survivors. Such factors are essential for formulating clear recommendations. For exposures with evidence of impacting pulmonary function, there is currently no effective intervention that reverses or delays pulmonary disease progression among asymptomatic survivors. Therefore, risk-benefit-assessments do not favour screening now. However, since extensive evidence shows smoking presents harmful effects on pulmonary health among the general population,

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

our panel agreed about counselling CAYA cancer survivors not to smoke. The panel further recommended vaccinations for CAYA cancer survivors at risk for pulmonary-related pathogens, as appropriate for other vulnerable populations (Table 4). Influenza vaccination is recommended based on concordance between existing guidelines. Based on local or national recommendations for populations with increased vulnerability of pulmonary disease, such as pneumococcus and SARS-CoV-2, the panel recommended considering additional vaccinations against bacteria or viruses. All three LTFU care guidelines mentioned informing anaesthetists about previous bleomycin treatment, yet without further information or support from included studies; our additional search showed contradictory findings (54, 55). Symptomatic CAYA cancer survivors For symptomatic CAYA cancer survivors—especially among those treated with allogeneic HSCT, thoracic radiotherapy, and thoracic surgery—our panel agreed upon readily performing PFT with results evaluated by pulmonologists experienced with CAYA cancer populations. Health care professionals and CAYA cancer survivors should heed symptoms, such as chronic cough, chest tightness, dyspnoea, wheezing, or exercise intolerance. Consideration of differential diagnoses, such as cardiac dysfunction, should guide selection of appropriate investigations. Pulmonologists from our guideline panel recommended spirometry, body plethysmography, and DLCO measurements wherever possible. Breath washout tests can additionally be performed if available. Fractional exhaled nitric oxide, bronchodilator reversibility tests, or other specific investigations should be used for differential diagnoses of other pulmonary dysfunction causes, which—even among vulnerable populations—are arguably more frequent reasons for pathological findings than previous cancer treatment, such as asthma in cases of obstructive disease. Managing cases of abnormal findings and frequency of further PFT depends on local institutions and guidance from local pulmonologists; it is not part of our recommendations. **DISCUSSION** Our review summarises existing guidelines, evidence from systematic literature searches, and harmonised recommendations for pulmonary dysfunction screening among CAYA cancer survivors diagnosed before age 30 with exposure to potentially lung-toxic cancer treatment modalities. Because

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

current evidence is scarce with quality limitations and because there are no effective treatments for asymptomatic pulmonary dysfunction, our panel limited recommendations for PFT to symptomatic CAYA cancer survivors only. We recommend health care providers to be aware of increased risks for possible pulmonary dysfunction—especially among survivors treated with allogeneic HSCT, thoracic radiotherapy, and thoracic surgery; be vigilant for early clinical symptoms of pulmonary dysfunction; and refer symptomatic CAYA cancer survivors to pulmonologists experienced with the population. We also recommend counselling all CAYA cancer survivors about lifestyle factors relevant for pulmonary and general health. Our recommendations are supported by two additional studies specific for children following HSCT (56, 57). Both studies were not considered in our final recommendation as they formulated follow-up recommendations independent of underlying diagnosis, including HSCT for malignant diseases, immune deficiencies, inherited bone marrow failure syndromes, and haemoglobinopathies. However, after two years of follow-up, neither study recommended regular PFT for asymptomatic children and adolescents; rather they advised considering follow-up PFT based on symptoms and past measurements (56, 57). Gaps in knowledge and future directions for research With currently available evidence, we only answered a few of our original clinical questions and often to only a limited extent, such as any exposure to radiotherapy without differentiation for doses or volumes. To improve evidence on pulmonary dysfunction among CAYA cancer survivors, we outlined gaps in knowledge and methodological approaches for future research (Table 5). We identified existing knowledge gaps for dose-response relationships of all studied exposures; newer chemotherapeutic or immunotherapeutic agents; other medical conditions, such as pulmonary complications during treatment, co-morbidities; impact of treatments on physiological processes affecting pulmonary function, such as lung growth and physiologic ageing; and also approaches for early assessment of pulmonary dysfunction and effects from preventive or curative interventions. Most studies focused on well-established risk factors such as HSCT (31-37), thoracic radiotherapy (1-3, 31, 38, 40, 45-48, 50-52), and thoracic surgery (1, 31, 38-40). For chemotherapeutic agents—even those with previously reported pulmonary toxicity, such as bleomycin— we found clinical evidence

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

for CAYA cancer survivors insufficient. Future studies evaluating other classical chemotherapeutic agents, targeted or immunotherapeutic agents, or pharmacovigilance data might identify new aspects of pulmonary dysfunction among CAYA cancer survivors. It is similar for radiotherapy, including a lack of data comparing photon and proton therapy where toxicity of protons might be lower from smaller irradiated volume compared with photons, possibly resulting in less lung-toxicity. For all exposures, we lack knowledge on how they interact with each other or how age at treatment or additional medical conditions modify impact from exposures; we also have little information about dose-response relationships. Peak lung function attained in early adulthood and the trajectory of lung function decline with ageing are important for lung health across the life span. The impact of cancer itself, pulmonary complications during treatment, pulmonary co-morbidities, such as asthma, or impaired somatic growth, such as scoliosis, on peak attained lung function has not been examined. No studies examined whether CAYA cancer survivors start at a lower peak attained lung function or whether physiological ageing and decline in pulmonary function is faster and steeper than among the general population. Frailty and accelerated ageing were previously described for childhood cancer survivors (58-60). The definition of frailty is met when fulfilling three or more of five criteria: reduced lean muscle mass, weakness, slow walking speed, low energy expenditure, and fatigue (61). Ness et al. showed that components of frailty—reduced strength, walking speed, and increased fatigue—were as frequent among childhood cancer survivors from the St. Jude Lifetime Cohort at a median age of 33 years as among people age 65 years and older in the general population (62). By calculating the deficit accumulation index score, Williams et al. showed childhood cancer survivors acquire more damage and disease than community controls (60). Both studies suggest accelerated ageing among childhood cancer survivors. Factors contributing to accelerated ageing and frailty include more rapid cellular senescence, telomere length reduction, epigenetic modifications, somatic mutations, and mitochondrial DNA damage (58). These factors may also affect lung growth and function among children and adolescents or result in faster pulmonary ageing, but their potential impact among CAYA cancer survivors is unknown.

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

Another gap in knowledge concerns measuring early stages of pulmonary dysfunction. Prior studies primarily utilized spirometry, body plethysmography, or DLCO measurement. More sensitive tests, such as multiple breath washout tests, may identify pulmonary disease earlier and eventually contribute to better understanding of pulmonary dysfunction development among CAYA cancer survivors. Parisi et al. and Schindera et al. investigated pulmonary function of childhood cancer survivors using multiple breath washout tests (63, 64). Parisi et al. investigated 57 survivors with median follow-up time of 6.2 years from end of treatment; they did not show differences in ventilation homogeneity compared with controls (64). The 46 survivors evaluated by Schindera et al. were median 20 years from cancer diagnosis (63). Survivors defined as high risk (bleomycin, busulfan, nitrosoureas, HSCT, thoracic radiotherapy, or surgery) tended to have more ventilation inhomogeneity than those at standard risk (other cancer therapies), yet not significantly (63). In both studies, more survivors had abnormal washout tests than abnormal spirometry. Available data made it impossible to reach conclusions about the longitudinal course of pulmonary function as survivors progress through childhood, puberty, and adulthood in their growth and development followed by a trajectory of ageing. Eight studies with repeated PFT results suffered from attrition bias, small sample sizes, and included sub-groups of CAYA cancer survivors, such as HSCT (2, 32, 33, 35, 37, 47, 52, 53). Ideally with baseline PFT before starting treatment, longitudinal data ascertained at regular intervals from diagnosis—will be available improve knowledge about the onset of pulmonary dysfunction and its evolution. PFT provides one way of assessing pulmonary health. Clinical symptoms or imaging are other possible modalities. Clinical symptoms lack objectivity and vary with age, which limits precise measurement. In addition, questions about clinical symptoms are worded differently between studies, which makes comparisons difficult. Louie et al validated selected self-reported complications from HSCT survivors (65). No data exist for other CAYA cancer survivor populations or for other questions about pulmonary dysfunction. We suggest future studies take weaknesses and methodological problems we identified from the literature we reviewed into account and avoid them whenever possible (Table 5). Collaboration between paediatric oncologists and pulmonologists helps avoid shortcomings when conducting PFT

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

and reporting results. Collaborative studies with harmonised protocols could maximise statistical power with larger numbers of CAYA cancer survivors and allow stratifying analyses into sub-groups defined by therapeutic exposures, age at treatment, cumulative doses, or genotype. Prospective rather than retrospective studies allow for standardising assessments, such as PFT at predefined time points, and minimise selection and attrition biases. Assessing patient-reported outcomes, such as symptoms, functional limitations, and quality of life, together with PFT, helps determine the clinical significance of findings and their impact on lives of patients and their families. To obtain accurate measurements, PFT must be performed to high standards, by trained personnel explicitly applying published guidelines and standards, including ERS/ATS guidelines. Reporting, interpreting, and applying results in clinical practice are equally important. It is essential that future studies use GLI reference equations to standardise PFT results and make them comparable between age groups and regions (66, 67). Binary cut-offs—describing results as either normal or abnormal reduce statistical power and introduce interpretations based on pre-defined threshold values. Since cutoff values differ between studies, such dichotomisation hampers comparisons of results, leading to conflicting and potentially misleading proportions of CAYA cancer survivors with pulmonary dysfunction. Reporting results as raw data and z-scores based on internationally agreed, age-adjusted reference values is preferred and allows comparing and pooling data. We suggest studies investigating pulmonary function among CAYA cancer survivors be conducted in the knowledge that at present no curative treatments exist for suspected progressive inflammatory and fibrotic changes underlying pulmonary dysfunction. Therefore, we advise careful study of benefits and harms from repeat testing. However, awareness of impaired pulmonary function possibly leads to earlier treatment of bacterial infections with antibiotics, especially because excess pulmonary mortality and hospitalisations among CAYA cancer survivors are mainly from infection (68, 69). The U.S. Food and Drug Administration and European Medicines Agency approved two anti-fibrotic drugs—pirfenidone and nintedanib—for the treatment of idiopathic pulmonary fibrosis; patients with progressive-fibrosing unclassifiable interstitial lung disease possibly also benefit (70). Therefore, in the future the possible benefit from anti-fibrotic drugs could be an area for investigation among CAYA cancer survivors.

Strengths and limitations

Strengths of our recommendation are multidisciplinary and international collaboration, which included perspectives from paediatric and adult specialists in CAYA cancer care and survivors; broad inclusion criteria; our thorough review process paired with in-depth quality assessment of included studies; and resulting evidence. Limitations mainly reflect lack of available evidence: studies with small sample sizes, heterogeneous PFT result reporting, use of different reference values; and scarce longitudinal data.

## Conclusion

CAYA cancer survivors treated with allogeneic HSCT, thoracic radiotherapy, and thoracic surgery were reported at risk for pulmonary dysfunction. However, our extensive literature search highlights the absence of robust evidence linking these exposures and pulmonary dysfunction because of small study sizes, high risks of bias, inconsistently assessing and reporting PFT results, and a lack of effective interventions to prevent the deterioration of asymptomatic pulmonary dysfunction. Therefore, our panel could not currently recommend routine PFT for asymptomatic CAYA cancer survivors. Yet, it is important for health care professionals and CAYA cancer survivors to be aware of possibly impaired pulmonary health and act vigilantly about appropriately investigating and following up when symptoms develop. We also recommend routine vaccinations recommended for people with pulmonary diseases and careful counselling relating to avoidance of tobacco products. Our results highlighted the current paucity of evidence, revealed relevant knowledge gaps, and emphasised that clearly defined, well-planned, harmonised, and collaborative studies and reports of pulmonary function outcomes are urgently needed to improve the body of evidence about pulmonary function among CAYA cancer survivors in the future.

# Acknowledgment

491

499

500

510

514515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540 541

542

543

- 492 We thank Elio Castagnola and Cecile Ronckers for their contribution to the title and abstract and full
- 493 text screening; Prof Thorsten Langer (Pediatric Oncology and Hematology, University Hospital for
- 494 Children and Adolescents, Lübeck, Germany) and Daniel Mulrooney (St Jude Children's Research
- 495 Hospital, Memphis, TN, USA) for critically appraising the recommendations and manuscript as
- 496 external reviewers; and Anna Apel (CEO of Saving Kids with Cancer Foundation, Poland; PanCare
- Board Member) and Katie Weyer as survivor representatives. Lastly, we thank Kristin Marie Bivens
- 498 (Institute of Social and Preventive Medicine, University of Bern) for her editorial assistance.

# **Author contributions**

- 501 Concept and design: CEK, ACD, RLM, SHA, MMH, LK, RK
- 502 Literature search: CEK, RLM, RK, MO
- Title and abstract screening: all authors
- Full text screening: all authors
- 505 Data extraction: all authors
- Risk of bias assessment: CEK, RLM, RK, MO, CS, MG, NW
- Quality of evidence assessment: CEK, RLM, RK, MO, CS, MG, NW
- Manuscript writing: all authors
- Manuscript review: all authors
- MO and RK have directly accessed and verified all underlying data reported in the manuscript.
- All authors had full access to all the data in the study and accept responsibility for the submission for
- 513 publication.

#### **Declaration of interest**

- AC Dietz is employed by and has equity in Shape Therapeutics, Inc. and was employed by and has equity in bluebird bio, Inc., neither of which provided financial support or oversight of this work.
- AB received fees for lectures and/or boards from Astra-Zeneca, Novartis, Enanta paid to her institution as well as travel grants from Boehringer and Astra-Zeneca.
- CEK received grants from the Swiss National Science Foundation
- DJW received grants/contracts from Vertex pharmaceuticals, Cystic Fibrosis Foundation,
- Cystic Fibrosis Foundation Therapeutic Development Network, payment or honoraria for lectures/ presentations by Cystic Fibrosis Foundation and American Board of Pediatrics
- GS and RK received support for the present manuscript by Bernische Krebsliga and Lungenliga Bern
- LSC received support from University of Alabama for COG Survivorship guidelines, royalties or licenses from Springer and Wolters Kluwer, payment or honoraria for lectures/ presentations from the American Society for Hematology and the University of Miami, travel support from the First International Pediatric Cardio-oncology meeting, and participates on the Data Safety Monitoring Board or Advisory Board of the NCI PDQ
- MG received a grant from the Swiss National Science Foundation, support for attending meetings and/or travel from the European Respiratory Society, has a leadership role in the BEAT-PCD ERS clinical research collaboration
- NW received general research support from CANSEARCH Research Foundation, payment/honoraria and support to attend an international meeting from Swedish Orphan Biovitrum (SOBI), participates on a Data Safety Monitoring Board or Advisory Board from SOBI
- PL received grants/contracts from Vertex and OM Pharma, payments or honoraria for lectures/ presentations by Vertex, Vifor and OM Pharma, participates on a Data Safety Monitoring Board or Advisory Board from Polyphor, Santhera, Vertex, OM Pharma, Vifor, Sanofi Aventis

544 - UH received a grant and support for attending meetings from the German Childhood Cancer Foundation,

# **Funding**

Swiss Cancer Research (grant no: KFS-4157-02-2017, KLS/KFS-4825-01-2019 and KFS-5302-02-2021), Cancer League Bern, Kinderkrebshilfe Schweiz, and Lung League Bern provided support for our study. Funders played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

#### References

- 1. Mulder RL, Thonissen NM, van der Pal HJ, Bresser P, Hanselaar W, Koning CC, et al. Pulmonary function impairment measured by pulmonary function tests in long-term survivors of childhood cancer. Thorax. 2011;66(12):1065-71.
- 2. Armenian SH, Landier W, Francisco L, Herrera C, Mills G, Siyahian A, et al. Long-term pulmonary function in survivors of childhood cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015;33(14):1592-600.
- 3. Green DM, Zhu L, Wang M, Ness KK, Krasin MJ, Bhakta NH, et al. Pulmonary function after treatment for childhood cancer. A report from the St. Jude Lifetime Cohort Study (SJLIFE). Annals of the American Thoracic Society. 2016;13(9):1575-85.
- 4. Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, et al. Long-term cause-specific mortality among survivors of childhood cancer. Jama. 2010;304(2):172-9.
- 5. Schindler M, Spycher BD, Ammann RA, Ansari M, Michel G, Kuehni CE, et al. Cause-specific long-term mortality in survivors of childhood cancer in Switzerland: A population-based study. International journal of cancer. 2016;139(2):322-33.
- 6. Huang TT, Hudson MM, Stokes DC, Krasin MJ, Spunt SL, Ness KK. Pulmonary outcomes in survivors of childhood cancer: a systematic review. Chest. 2011;140(4):881-901.
- 7. Skinner R, Kaplan R, Nathan PC. Renal and pulmonary late effects of cancer therapy. Seminars in oncology. 2013;40(6):757-73.
- 8. Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone marrow transplantation. 2011;46:1283.
- 9. Saglio F, Zecca M, Pagliara D, Giorgiani G, Balduzzi A, Calore E, et al. Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study. Bone marrow transplantation. 2020;55(10):1918-27.
- Straub JM, New J, Hamilton CD, Lominska C, Shnayder Y, Thomas SM. Radiation-induced fibrosis: mechanisms and implications for therapy. J Cancer Res Clin Oncol. 2015;141(11):1985-94.
- 586 11. Robinson PD, Latzin P, Verbanck S, Hall GL, Horsley A, Gappa M, et al. Consensus statement for inert gas washout measurement using multiple- and single- breath tests. The European respiratory journal. 2013;41(3):507-22.
- 589 12. Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy S, Wethal T, et al. Diffusing 590 capacity impairment is prevalent in long-term lymphoma survivors after high-dose therapy with 591 autologous stem cell transplantation. Bone marrow transplantation. 2016;52:646.
- 592 13. Botta L, Gatta G, Capocaccia R, Stiller C, Cañete A, Dal Maso L, et al. Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study. The Lancet Oncology. 2022;23(12):1525-36.
- 595 14. Children's Oncology Group Long Term Follow-Up guidelines Version 5.0 2018 [cited 2019 05.04.2019]. Available from:
- 597 http://www.survivorshipguidelines.org/pdf/2018/COG\_LTFU\_Guidelines\_v5.pdf.

- 598 15. Dutch Children's Oncology Group SKION. Guidelines for follow-up in survivors of childhood cancer 5 years after diagnosis. 2010 [cited 08.05.2018]. Available from:
- https://www.skion.nl/voor-patienten-en-ouders/late-effecten/533/richtlijn-follow-up-na-kinderkanker/.
- 602 16. United Kindgdom Chilren's Cancer Study Group. Therapy based long term follow-up Practice Statement 2005. [cited 08.05.2018]. Available from:
- https://www.cclg.org.uk/write/MediaUploads/Member%20area/Treatment%20guidelines/LTFU full.pdf.
- 17. International Guideline Harmonization Group (IGHG). [cited 04.11.2020]. Available from: https://www.ighg.org/.
- 608 18. Kremer LC, Mulder RL, Oeffinger KC, Bhatia S, Landier W, Levitt G, et al. A worldwide 609 collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult 610 cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline 611 Harmonization Group. Pediatric blood & cancer. 2013;60(4):543-9.
- 612 19. Children's Oncology Group Long Term Follow-Up guidelines Version 4.0 2013 [cited 0.05.2018]. Available from: https://www.childrensoncologygroup.org/.
- 614 20. Children's Cancer and Leukaemia Group. [cited 29.05.2022]. Available from: https://www.cclg.org.uk/.
- 21. PanCare Pan-European Network for Care of Survivors after Childhood and Adolescent Cancer. [cited 29.05.2022]. Available from: www.pancare.eu.
- Scottish Intercollegiate Guidelines Network (SIGN). Long term follow up of survivors of childhood cancer A national clinical guideline 2013. [cited 16.11.2021]. Available from: https://www.sign.ac.uk/media/1070/sign132.pdf.
- Centre for Evidence-Based Medicine (CEBM). Asking focused questions: University of Oxford,
   Oxford UK. [cited 29.05.2022]. Available from: https://www.cebm.ox.ac.uk/resources/ebm-tools/asking-focused-questions.
- Otth M, Schindera C, Güngör T, Ansari M, Scheinemann K, Belle FN, et al. Transplant
   characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after
   hematopoietic stem cell transplantation-a cohort study. Bone marrow transplantation. 2021;
   56(5):1065-1076.
- Kasteler R, Weiss A, Schindler M, Sommer G, Latzin P, von der Weid NX, et al. Long-term pulmonary disease among Swiss childhood cancer survivors. Pediatric blood & cancer.
   2018;65(1).
- Dietz AC, Chen Y, Yasui Y, Ness KK, Hagood JS, Chow EJ, et al. Risk and impact of
   pulmonary complications in survivors of childhood cancer: A report from the Childhood Cancer
   Survivor Study. Cancer. 2016;122(23):3687-96.
- 634 27. Mertens AC, Yasui Y, Liu Y, Stovall M, Hutchinson R, Ginsberg J, et al. Pulmonary 635 complications in survivors of childhood and adolescent cancer. A report from the Childhood 636 Cancer Survivor Study. Cancer. 2002;95(11):2431-41.
- 637 28. Huang TT, Chen Y, Dietz AC, Yasui Y, Donaldson SS, Stokes DC, et al. Pulmonary outcomes 638 in survivors of childhood central nervous system malignancies: a report from the Childhood 639 Cancer Survivor Study. Pediatric blood & cancer. 2014;61(2):319-25.
- 640 29. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336-41.
- 642 30. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
- 644 31. Record E, Williamson R, Wasilewski-Masker K, Mertens AC, Meacham LR, Popler J. Analysis 645 of risk factors for abnormal pulmonary function in pediatric cancer survivors. Pediatric blood & 646 cancer. 2016;63(7):1264-71.
- Inaba H, Yang J, Pan J, Stokes DC, Krasin MJ, Srinivasan A, et al. Pulmonary dysfunction in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell transplantation. Cancer. 2010;116(8):2020-30.
- 650 33. Ginsberg JP, Aplenc R, McDonough J, Bethel J, Doyle J, Weiner DJ. Pre-transplant lung function is predictive of survival following pediatric bone marrow transplantation. Pediatric blood & cancer. 2010;54(3):454-60.

- 653 34. Leung W, Ahn H, Rose SR, Phipps S, Smith T, Gan K, et al. A prospective cohort study of late 654 sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine. 655 2007;86(4):215-24.
- 656 35. Madanat-Harjuoja LM, Valjento S, Vettenranta K, Kajosaari M, Dyba T, Taskinen M. 657 Pulmonary function following allogeneic stem cell transplantation in childhood: a retrospective 658 cohort study of 51 patients. Pediatric transplantation. 2014;18(6):617-24.

660

661

662

663

671

673

674

677

681

682

683

684

687

688

689

690

691

695

696

697

- 36. Hoffmeister PA, Madtes DK, Storer BE, Sanders JE. Pulmonary function in long-term survivors of pediatric hematopoietic cell transplantation. Pediatric blood & cancer. 2006;47(5):594-606.
  - 37. Wieringa J, van Kralingen KW, Sont JK, Bresters D. Pulmonary function impairment in children following hematopoietic stem cell transplantation. Pediatric blood & cancer. 2005;45(3):318-23.
- 664 38. De A, Kamath S, Wong K, Olch AJ, Malvar J, Sposto R, et al. Correlation of pulmonary 665 function abnormalities with dose volume histograms in children treated with lung irradiation. 666 Pediatric pulmonology. 2015;50(6):596-603.
- 667 39. Denbo JW, Zhu L, Srivastava D, Stokes DC, Srinivasan S, Hudson MM, et al. Long-term 668 pulmonary function after metastasectomy for childhood osteosarcoma: a report from the St Jude 669 lifetime cohort study. Journal of the American College of Surgeons. 2014;219(2):265-71.
- 670 40. Stone A, Friedman DN, Kushner BH, Wolden S, Modak S, LaQuaglia MP, et al. Assessment of pulmonary outcomes, exercise capacity, and longitudinal changes in lung function in pediatric 672 survivors of high-risk neuroblastoma. Pediatric blood & cancer. 2019;66(11):e27960.
  - 41. Nysom K, Holm K, Hertz H, Hesse B. Risk factors for reduced pulmonary function after malignant lymphoma in childhood. Medical and pediatric oncology. 1998;30(4):240-8.
- 675 42. Nysom K, Holm K, Olsen JH, Hertz H, Hesse B. Pulmonary function after treatment for acute 676 lymphoblastic leukaemia in childhood. British journal of cancer. 1998;78(1):21-7.
- 43. Oancea SC, Gurney JG, Ness KK, Ojha RP, Tyc VL, Klosky JL, et al. Cigarette smoking and 678 pulmonary function in adult survivors of childhood cancer exposed to pulmonary-toxic therapy: 679 results from the St. Jude lifetime cohort study. Cancer epidemiology, biomarkers & prevention. 680 2014;23(9):1938-43.
  - 44. Myrdal OH, Kanellopoulos A, Christensen JR, Ruud E, Edvardsen E, Kongerud J, et al. Risk factors for impaired pulmonary function and cardiorespiratory fitness in very long-term adult survivors of childhood acute lymphoblastic leukemia after treatment with chemotherapy only. Acta oncologica (Stockholm, Sweden). 2018;57(5):658-64.
- 685 45. Zorzi AP, Yang CL, Dell S, Nathan PC. Bleomycin-associated Lung Toxicity in Childhood 686 Cancer Survivors. Journal of pediatric hematology/oncology. 2015;37(8):e447-52.
  - 46. Jenney ME, Faragher EB, Jones PH, Woodcock A. Lung function and exercise capacity in survivors of childhood leukaemia. Medical and pediatric oncology. 1995;24(4):222-30.
  - 47. Green DM, Merchant TE, Billups CA, Stokes DC, Broniscer A, Bartels U, et al. Pulmonary function after treatment for embryonal brain tumors on SJMB03 that included craniospinal irradiation. International journal of radiation oncology, biology, physics. 2015;93(1):47-53.
- 692 48. Khan F, Williams AM, Weiner DJ, Constine LS. Impact of Respiratory Developmental Stage on 693 Sensitivity to Late Effects of Radiation in Pediatric Cancer Survivors. Adv Radiat Oncol. 694 2020;5(3):426-33.
  - 49. Mittal A, Bhethanabhotla S, Ganguly S, Vishnubhatla S, Khadgawat R, Patel C, et al. Late effects in pediatric Hodgkin lymphoma survivors after uniform treatment with ABVD with or without radiotherapy. Pediatric blood & cancer. 2021;68(11):e29293.
- 698 50. Weiner DJ, Maity A, Carlson CA, Ginsberg JP. Pulmonary function abnormalities in children 699 treated with whole lung irradiation. Pediatric blood & cancer. 2006;46(2):222-7.
- 700 51. Oguz A, Tayfun T, Citak EC, Karadeniz C, Tatlicioglu T, Boyunaga O, et al. Long-term 701 pulmonary function in survivors of childhood Hodgkin disease and non-Hodgkin lymphoma. 702 Pediatric blood & cancer. 2007;49(5):699-703.
- 703 52. Otth M, Yammine S, Usemann J, Latzin P, Mader L, Spycher B, et al. Longitudinal lung 704 function in childhood cancer survivors after hematopoietic stem cell transplantation. Bone 705 marrow transplantation. 2022;57(2):207-14.
- 706 53. Marina NM, Greenwald CA, Fairclough DL, Thompson EI, Wilimas JA, Mackert PW, et al. 707 Serial pulmonary function studies in children treated for newly diagnosed Hodgkin's disease 708 with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine

- alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Cancer. 1995;75(7):1706-11.
- 711 54. Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? The Journal of urology. 1998;160(4):1347-52.

714

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

751


752

753

754

764

- 55. LaMantia KR, Glick JH, Marshall BE. Supplemental oxygen does not cause respiratory failure in bleomycin-treated surgical patients. Anesthesiology. 1984;60(1):65-7.
- 715 56. Chow EJ, Anderson L, Baker KS, Bhatia S, Guilcher GMT, Huang JT, et al. Late Effects
   716 Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell
   717 Transplantation: A Children's Oncology Group Report. Biology of Blood and Marrow
   718 Transplantation. 2016;22(5):782-95.
- Dietz AC, Duncan CN, Alter BP, Bresters D, Cowan MJ, Notarangelo L, et al. The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biology of Blood and Marrow Transplantation. 2017;23(1):24-9.
- Ness KK, Kirkland JL, Gramatges MM, Wang Z, Kundu M, McCastlain K, et al. Premature
   Physiologic Aging as a Paradigm for Understanding Increased Risk of Adverse Health Across
   the Lifespan of Survivors of Childhood Cancer. Journal of clinical oncology. 2018;36(21):2206 15.
  - 59. Armenian SH, Gibson CJ, Rockne RC, Ness KK. Premature Aging in Young Cancer Survivors. Journal of the National Cancer Institute. 2019;111(3):226-32.
  - 60. Williams AM, Mandelblatt J, Wang M, Armstrong GT, Bhakta N, Brinkman TM, et al. Premature aging as an accumulation of deficits in young adult survivors of pediatric cancer. Journal of the National Cancer Institute. 2023;115(2):200-7.
  - 61. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-56.
    - 62. Ness KK, Krull KR, Jones KE, Mulrooney DA, Armstrong GT, Green DM, et al. Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St Jude Lifetime cohort study. Journal of clinical oncology. 2013;31(36):4496-503.
    - 63. Schindera C, Usemann J, Zuercher SJ, Jung R, Kasteler R, Frauchiger B, et al. Pulmonary Dysfunction after Treatment for Childhood Cancer. Comparing Multiple-Breath Washout with Spirometry. Annals of the American Thoracic Society. 2021;18(2):281-9.
    - 64. Parisi GF, Cannata E, Manti S, Papale M, Meli M, Russo G, et al. Lung clearance index: A new measure of late lung complications of cancer therapy in children. Pediatric pulmonology. 2020;55(12):3450-6.
    - 65. Louie AD, Robison LL, Bogue M, Hyde S, Forman SJ, Bhatia S. Validation of self-reported complications by bone marrow transplantation survivors. Bone marrow transplantation. 2000;25(11):1191-6.
- 748 66. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference 749 values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. The 750 European respiratory journal. 2012;40(6):1324-43.
  - 67. Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. American journal of respiratory and critical care medicine. 2019;200(8):e70-e88.
- 755 68. Fidler MM, Reulen RC, Bright CJ, Henson KE, Kelly JS, Jenney M, et al. Respiratory mortality of childhood, adolescent and young adult cancer survivors. Thorax. 2018;73(10):959-68.
- 757 69. Smith L, Glaser AW, Peckham D, Greenwood DC, Feltbower RG. Respiratory morbidity in young people surviving cancer: Population-based study of hospital admissions, treatment-related risk factors and subsequent mortality. International journal of cancer. 2018;145(1):20-8.
- 760 70. Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in
   761 patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind,
   762 randomised, placebo-controlled, phase 2 trial. The Lancet Respiratory medicine. 2020;8(2):147 763 57.



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.

Figure 1: Flow diagram for selection of studies

(Studies could be included in more than one category)

Table 1: Key characteristics of included studies used for recommendation (n=26). Detailed information available in Appendix K.

Author  Armenian et al., J Clin Oncol, 2015 <sup>2</sup>	<ol> <li>Population         <ol> <li>Number of survivors analysed (treatment years)</li> <li>Diagnostic group</li> <li>Proportion of survivors exposed to specific treatments</li> <li>N=121 (1972–2007)</li> </ol> </li> <li>Treatment-related inclusion criteria: no restriction for cancer diagnosis, at least one pulmonary toxic treatment modality (1) pulmonary toxic chemotherapy (bleomycin, busulfan, nitrosoureas), and/or 2) chest radiation, and/or 3) allogeneic HSCT with cGVHD, and/or 4) pulmonary surgery (lobectomy, metastasectomy, or wedge resection)</li> <li>Exposure/PICO: Bleomycin 35%, busulfan 12%, nitrosoureas 10%, radiotherapy 74%, surgery 6%, HSCT 36%</li> </ol>	Outcome relevant for recommendation  1. Pulmonary function parameters assessed  2. Definition of pulmonary dysfunction  1. TLC, FVC, FEV1, FEV1/FVC, DLCO  2. Obstructive=FEV1/FVC<0·7, FEV1<80% pred Restrictive= TLC<75% pred, FEV1≥80% pred Diffusion capacity impairment =DLCO<75% pred
De et al., Pediatr Pulmonol, 2015 <sup>38</sup>	<ol> <li>N=49 (1999–2009)</li> <li>Treatment-related inclusion criteria: no restriction for cancer diagnosis, radiotherapy involving the lung</li> <li>Exposure/PICO: Bleomycin 78%, cyclophosphamide 82%, radiotherapy 100%, surgery 18%</li> </ol>	<ol> <li>FEV1, FVC, FEV1/FVC, FEF25–75, RV, TLC. RV/TLC, phase II N<sub>2</sub>, DLCO</li> <li>Obstructive=FEV1/FVC &lt;80% pred or abnormal FEV1 or FEF25–75% pred with normal lung volumes (i.e., normal TLC) Restrictive=TLC &lt;77% pred Hyperinflation= RV/TLC ratio &gt;28% Diffusion capacity impairment= DLCOadj &lt;65% pred or DLCOadj/VA &lt;4 ml/mm/Hg/min/L</li> </ol>
Denbo et al., J Am Coll Surg, 2014 <sup>39</sup>	<ol> <li>N=21 (1968–1998)</li> <li>Treatment-related inclusion criteria: diagnosis of osteosarcoma and pulmonary metastasectomy</li> <li>Exposure/PICO: Bleomycin 28%, surgery 100%</li> </ol>	1. FVC, FEV1, TLC, DLCO 2. Threshold for pathological parameters=FVC <80% pred; FEV1 <80% pred; TLC <75% pred; DLCOcorr <75% pred Obstructive=FEV1/FVC < 0.70 Restrictive=TLC <75% pred
Ginsberg et al., PBC, 2010 <sup>33</sup>	<ol> <li>N=317 (1978–2005)</li> <li>Treatment-related inclusion criterion: first myeloablative SCT (autologous or allogeneic) and at least one PFT available</li> <li>Exposure/PICO: Allogeneic SCT 76%, TBI 55%</li> </ol>	1. FEV1, FVC, TLC, FEF25–75, FVC, TLC, DLCO 2. Threshold for pathological parameters=FEV1, FEF25–75%, FVC, TLC, DLCO as z-scores if below -2 z-scores

-		
Green et al., Int J Radiat	1. N=260 (2003–2010)	1. FEV1, FVC, TLC, DLCO
Oncol Biol Phys, 2015 <sup>47</sup>	2. Treatment-related inclusion criterion: embryonal brain tumors	2. Threshold for pathological parameters=FEV1<80%pred, FVC <80%pred, DLCO<75%pred, TLC<75% pred
	3. Exposure/PICO: Cyclophosphamide 100%,	
	craniospinal radiotherapy 100%	
Green et al., Ann Am	1. N=606 (unknown, SJLIFE)	1. FEV1, FVC, TLC, DLCO
Thorac Soc, 2016 <sup>3</sup>	2. Treatment-related inclusion criteria: no restriction for cancer diagnosis, at least one pulmonary toxic treatment modality (1) bleomycin, busulfan, BCNU, or CCNU; and/or (2) radiation therapy to the chest, whole lung, mediastinum, axilla, mini-mantle, mantle, extended mantle, total lymphoid irradiation, subtotal lymphoid irradiation, or total body irradiation; and/or (3) surgical procedures (pulmonary lobectomy, metastasectomy, or wedge resection), at least one PFT measurement 3. Exposure/PICO: Bleomycin 21·3%, busulfan 2·6%, cyclophosphamide 64.5%, nitrosoureas 3.8%,	2. Threshold for pathological parameters=FEV1<80%pred, FVC<80%pred, FEV1/FVC<0·7, TLC<75%pred, DLCOcorr<75%pred
II CC ' + 1 DDC	radiotherapy 76·7%, surgery 19·7%, HSCT 6·6%	
Hoffmeister et al., PBC, 2006 <sup>36</sup>	<ol> <li>N=215 (1969–1995)</li> <li>Treatment-related inclusion criterion: myeloablative HSCT</li> <li>Exposure/PICO: Cyclophosphamide proportion not reported, TBI 88%</li> </ol>	1. FEV1, FVC, FEV1/FVC, TLC, DLCO 2. Threshold for pathological parameters=TLC<80%, FVC, FEV1, FEV1/FVC<80%, DLCO<70%
Inaba et al., Cancer,	1. N=89 (1990–2005)	1. FEV1, FVC, TLC, DLCO, FEF25–75, RV, FRC
2010 <sup>32</sup>	<ol> <li>Treatment-related inclusion criteria: allogeneic HSCT and available PFT before HSCT</li> <li>Exposure/PICO: Cyclophosphamide 95%, radiotherapy (TBI) 97%</li> </ol>	2. Threshold for pathological parameters=FEV1, FVC, TLC, DLCOcorr <80%pred, FEF25-75 <67%pred, RV and FRC >120%pred. FEV1/FVC<0·8. RV/TLC>0·3.  Obstructive=FEV1/FVC<0·8, FEV1<80%pred, FEF25-75 <67%pred Restrictive=FVC<80%pred, TLC<80%pred,
Jenney et al., Med	1. N=69 (1954–1988)	1. EV1, FVC, RV, FRC, ITGV, RAW, SGAW, TLC, DLCO
Pediatr Oncol, 1995 <sup>46</sup>	<ol> <li>Treatment-related inclusion criterion: acute leukaemia, at least one PFT available</li> <li>Exposure/PICO: Cyclophosphamide (proportion not reported), craniospinal irradiation 14%</li> </ol>	2. Threshold for pathological parameters=FEV1, FVC, RV, FRC, ITGV, RAW, SGAW, TLC, DLCO analyzed as <80% pred and <85% pred

Khan et al., Adv Radiat Oncol, 2020 <sup>48</sup>	<ol> <li>N=61 (1995–2016)</li> <li>Treatment-related inclusion criteria: no restriction for cancer diagnosis, radiotherapy to the lung</li> <li>Exposure/PICO: Bleomycin 59%, radiotherapy 100%</li> </ol>	1. FEV1, FVC, FVC, TLC, DLCO 2. Obstructive=FVC z-score >-1·645, FEV1 z-score <-1·645, FEV1/FVC ratio z-score <-1·645. Restrictive=TLC z-score <-1·645. Hyperinflation=RV/TLC ratio z-score >+1·645. DLCO z-score <-1·645
Leung et al., Medicines (Baltimore), 2007 <sup>34</sup>	<ol> <li>N=155 (1990–2003)</li> <li>Treatment-related inclusion criteria: no restriction for cancer diagnosis, allogeneic HSCT</li> <li>Exposure/PICO: Allogeneic HSCT 100%, TBI 79%</li> </ol>	1. FEV1, FVC, FEV1/FVC, TLC, DLCO 2. Threshold for pathological parameters=FEV1/FVC<85%pred, TLC and DLCO <80%pred
Madanat-Harjuoja et al., Pediatr Transplant, 2014 <sup>35</sup>	<ol> <li>N=51 (1993–2005)</li> <li>Treatment-related inclusion criteria: no restriction for cancer diagnosis, allogeneic HSCT</li> <li>Exposure/PICO: Cyclophosphamide 47%, TBI 98%, total nodal irradiation 2%</li> </ol>	1. FEV1, FVC, FEV1/FVC 2. Obstructive=FEV1<80% and FEV1/FVC<80% Restrictive=FVC<80% and FEV1/FVC>80%
Marina et al., Cancer, 1995 <sup>53</sup>	1. N=37 (1983–1988) 2. Treatment-related inclusion criteria: Hodgkin lymphoma plus mantle radiotherapy plus chemotherapy with COP and ABVD 3. Exposure/PICO: Bleomycin 100%, mantle radiotherapy 100%	<ol> <li>VC, TLC, DLCO</li> <li>Threshold for pathological parameters=FVC, TLC, DLCO, DLCO/VA as %predicted; no cut-off values defined</li> </ol>
Mittal et al., PBC, 2021 <sup>49</sup>	1. N=154 (2003–2013) 2. Treatment-related inclusion criteria: Hodgkin lymphoma 3. Exposure/PICO: Bleomycin 100%	1. FEV1, FVC, DLCO 2. Threshold for pathological parameters=FEV1, FVC, DLCO <80% pred Restrictive=FVC<80% pred, FEV1/FVC≥85 Mixed=FVC<80% pred, FEV1/FVC<85
Mulder et al., Thorax, 2011 <sup>1</sup>	<ol> <li>N=193 (1966–1996)</li> <li>Treatment-related inclusion criteria: no restriction for cancer diagnosis, at least one pulmonary toxic treatment modality (bleomycin, pulmonary radiotherapy and/or pulmonary surgery)</li> <li>Exposure/PICO: Bleomycin 57%, radiotherapy 40.9%, surgery 16.6%</li> </ol>	1. TLC, FVC, FEV1, FEV1/VC, DLCO 2. Obstructive=FEV1/VC <sub>max</sub> <0.70 and FEV1<80% pred Restrictive=TLC <75% pred or FVC <75% pred with normal FEV1/VC <sub>max</sub> ratio if no TLC available Diffusion capacity impairment=DLCO or KCO <75% pred

Myrdal et al., Acta Oncol, 2018 <sup>44</sup>	<ol> <li>N=116 (1970–2002)</li> <li>Treatment-related inclusion criteria: acute lymphoblastic leukaemia (chemotherapy only)</li> <li>Exposure/PICO: Smoking 19%</li> </ol>	1. FEV1, FVC, FEV1/FVC, TLC, RV, DLCO 2. Threshold for pathological parameters=FVC, FEV1, FE1/FVC, TLC, RV, DLCO, DLCO/VA; reported as absolute values and percentage of predicted Obstructive= FEV1/FVC <0.7 Restrictive and DLCO impairment= <80% pred
Nysom et al., Br J Cancer, 1998 <sup>42</sup>	<ol> <li>N=94 (1970–1990)</li> <li>Treatment-related inclusion criteria: Acute lymphoblastic leukaemia</li> <li>Exposure/PICO: Cyclophosphamide 46%, methotrexate 73%, smoking (former or current) 23%</li> </ol>	1. FEV1, FVC, TLC, DLCO 2. Threshold for pathological parameters=FEV1, FVC, TLC, DLCO as z-scores, abnormal if >1.645 residual SD from predicted mean values Obstructive=low FEV1/FVC Restrictive=reduced FVC or TLC or restrictive flow-volume curve
Nysom et al., Med Padiatr Oncol, 1998 <sup>41</sup>	<ol> <li>N=41 (1970–1992)</li> <li>Treatment-related inclusion criteria: Hodgkin and non-Hodgkin lymphoma</li> <li>Exposure/PICO: Radiotherapy 51%</li> </ol>	1. FEV1, FVC, TLC, DLCO 2. Threshold for pathological parameters=FEV1, FVC, TLC, DLCO as z-scores, abnormal if >1.645 residual SD from predicted mean values
Oancea et al., Cancer Epidemiol Biomarkers Prev, 2014 <sup>43</sup>	1. N=433 (unknown) 2. Treatment-related inclusion criteria: no restriction for cancer diagnosis, at least one pulmonary toxic treatment modality (pulmonary lobectomy, metastasectomy or wedge resection, bleomycin, busulfan, lomustine, carmustine, or radiotherapy to the chest, whole lung, mediastinum, axilla, minimantle, mantle, extended mantle, total lymphoid irradiation, subtotal lymphoid irradiation, or total body irradiation) 3. Exposure/PICO: Bleomycin 22%, busulfan 2%, nitrosoureas 4%, radiotherapy 81%, surgery 17%	1. FEV1, FVC, TLC, DLCO 2. Obstructive=FEV1/FVC <0·70 Restrictive=TLC< 75% pred
Oguz et al., PBC, 2007 <sup>51</sup>	N=75 (1992–2003)     Treatment-related inclusion criteria: Hodgkin and non-Hodgkin lymphoma     Exposure/PICO: Radiotherapy 55%	1. FEV1, FVC, FEV1/FVC, TLC, RV, RV/TLC, DLCO 2. Obstructive by FEV1, FVC, FEV1/FVC. Restrictive by TLC, RV, RV/TLC ratio. Diffusion capacity impairment by DLCO. No further information.
Otth et al., Bone Marrow Transplant, 2022 <sup>52</sup>	<ol> <li>N=74 (1976–2010)</li> <li>Treatment-related inclusion criteria: autologous or allogeneic HSCT</li> <li>Exposure/PICO: Radiotherapy 70%, thoracic surgery 14%, allogeneic HSCT, 68%, busulfan 34%, carmustine 7%, lomustine 1%, bleomycin 5%</li> </ol>	1. FEV1, FVC, MMEF, TLC, RV, DLCO 2. Threshold for pathological parameters=FEV1, FVC, MMEF, TLC, RV, DLCO as z-scores, abnormal if z-scores <-1·645

Record et al., PBC, 2016 <sup>31</sup>	<ol> <li>N=143 (2000–2009)</li> <li>Treatment-related inclusion criteria: no restriction for cancer diagnosis, at least one pulmonary toxic treatment modality (bleomycin, busulfan, carmustine, lomustine; radiation to the chest (mantle, mediastinal, whole lung fields), abdomen (whole abdomen, upper abdominal field), or TBI; or surgery to the chest or lung (lobectomy, wedge resection, or thoracotomy))</li> <li>Exposure/PICO: Bleomycin 33·6%, nitrosoureas 11·9%, radiotherapy 67·8%, surgery 16·8%, HSCT 46·9%</li> </ol>	1. FEV1, FVC, FEV1/FVC, FEF25-75, TLC, RV 2. Obstructive= FVC <80% pred.; FEV1<80% pred or FEV1/FVC<80% pred, or FEF25-75% <68% pred Restrictive=TLC <80% pred Hyperinflation=RV>120% pred or RV/TLC >28% pred
Stone et al., PBC, 2020 <sup>40</sup>	<ol> <li>N=62 (1996–2013)</li> <li>Treatment-related inclusion criteria: High-risk neuroblastoma</li> <li>Exposure/PICO: Busulfan 6.5%, cyclophosphamide</li> </ol>	1. FEV1, FVC, FEF25-75, TLC, DLCO 2. Threshold for pathological parameters=FEV1, FVC, TLC, DLCO <80% pred Obstructive=FEV1/FVC<0.8
Weiner et al., PBC, 2006 <sup>50</sup>	<ol> <li>100%, radiotherapy 34%, surgery 23%</li> <li>N=30 (1988–2003)</li> <li>Treatment-related inclusion criteria: no restriction to cancer diagnosis, whole lung irradiation</li> <li>Exposure/PICO: Bleomycin 10%, radiotherapy 100%</li> </ol>	Restrictive=TLC<80 %pred 1. FVC, FEV1, FEV1/FVC, TLC, DLCO, MIP, MEP 2. Each pulmonary function parameter was considered normal if it was within two standard deviations of the mean (-2 <z<2)< td=""></z<2)<>
Wieringa et al., PBC, 2005 <sup>37</sup>	<ol> <li>N=39 (2001–2003)</li> <li>Treatment-related inclusion criteria: no restriction to cancer diagnosis, allogeneic HSCT</li> <li>Exposure/PICO: Cyclophosphamide 100%, TBI or thoracoabdominal irradiation 79%, busulfan 15%</li> </ol>	1. FEV1, FVC, FRC, RV, TLCO 2. Threshold for pathological parameters=FEV1, FVC, FRC, RV, TLCO, pathological when <80% predicted Obstructive=FEV1/FVC < 80% pred Restrictive=TLC <80% pred Diffusion capacity impairment=TLCO <80% pred
Zorzi et al., J Pediatr Hematol Oncol, 2015 <sup>45</sup>	<ol> <li>N=143 (1997–2010)</li> <li>Treatment-related inclusion criteria: Hodgkin lymphoma, extracranial germ cell tumors</li> <li>Exposure/PICO: Bleomycin 100%; radiotherapy 60%, smoking 2%</li> </ol>	1. FVC, TLC, RV, DLCO 2. Threshold for pathological parameters=TLC<80% pred, FVC <80% pred, DLCO <80% pred Obstructive=abnormal FVC, normal TLC and RV/TLC >=30% and scooped flow-volume loop Restrictive=reference to Pellegrino et al

Abbreviations: ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; COP, cyclophosphamide, vincristine, prednisone; DLCO, diffusion capacity for carbon monoxide; FVC, forced vital capacity; HSCT, hematopoietic stem cell transplantation; MIP, maximum inspiratory pressure; MEP, maximum expiratory pressure; n, number; PFT, pulmonary function testing; pred., predicted; SD, standard deviation; SCT, stem cell transplantation; TBI, total body irradiation; TLC, total lung capacity.

Table 2: Conclusions and quality of the evidence for the risk and risk factors for pulmonary function impairment among childhood, adolescent, and young adult cancer survivors diagnosed up to age 30.

		Obstructive*	Restrictive*	Hyperinflation*	Diffusion capacity*
	Yes/no	= Very low <sup>31</sup> ↑ Low <sup>32,33</sup>	= Very low <sup>31</sup>	↑ Very low <sup>31</sup>	No study
	Age	↑ Low <sup>32,33</sup>	= Very low <sup>33,37</sup>	NS	↑ Very low <sup>32,33,34</sup>
HSCT	GvHD	↑ Very low <sup>35,36</sup>	↑ Very low <sup>35</sup>	NS	↑ Low <sup>34</sup>
	Infection	NS	NS	NS	NS
	TBI	$= Very low^{34,36}$	↑ Very low <sup>34,36</sup>	NS	↑ Moderate <sup>34</sup>
	Yes/no	↑ Very low <sup>46</sup>	↑ Very low <sup>1,46</sup>	NS	= Low <sup>1</sup>
Cyclophosphamide	Higher dose	= Very low (Green 2015)	↑ Very low (Green 1998)	NS	NS
	Age	NS	NS	NS	NS
	Yes/no	NS	NS	NS	NS
Methotrexate	Higher dose	NS	= Very low <sup>42</sup>	NS	NS
	Age	NS	NS	NS	NS
Gemcitabine		NS	NS	NS	NS
	Yes/no	↓ Very low <sup>31,38,39</sup>	=Very low <sup>1,2,31,38,39</sup>	↓ Very low <sup>31,38</sup>	$= Very low^{1,2,38,39}$
Bleomycin	Higher dose	=Very low <sup>31</sup>	↑ Very low <sup>31</sup>	= Very low <sup>31</sup>	$= \text{Very low}^{45,49,53}$
	Age	NS	NS	NS	NS
	Yes/no	NS	= Very low <sup>2</sup>	NS	= Very low <sup>2</sup>
Busulfan	Higher dose	NS	NS	NS	NS
	Age	NS	NS	NS	NS
	Yes/no	NS	= Very low <sup>2</sup>	No study	= Very low <sup>2</sup>
Nitrosourea	Higher dose	NS	NS	NS	NS
	Age	NS	NS	NS	NS
	Yes/no	↑ Very low <sup>31,40,46,51,52</sup>	↑ Very low <sup>1,31,40,46,51,52</sup>		↑ Very low <sup>1,40,454,46,51,52</sup>
Do diothonous	Higher dose	↑ Very low <sup>3,38,50</sup>	↑ Very low <sup>2,3,38,47,50</sup>	↑ Very low <sup>38</sup>	↑ Very low <sup>2,3,38,47,50</sup>
Radiotherapy	Field	NS	NS	NS	NS
	Age	$= \text{Very low}^{38,48,50}$	$= \text{Very low}^{38,48,50}$	= Very low <sup>38</sup>	= Very low <sup>38,48,50</sup>
	Radiosensitizer	NS	NS	NS	NS

	Yes/no	↑ Very low <sup>31,38,39,40</sup>	↑ Very low <sup>1,31,38,39,40</sup>	= Very low <sup>31,38</sup>	= Very low <sup>1,38,39,40</sup>
Surgery	Resection volume	NS	NS	NS	NS
	Age	NS	NS	NS	NS
	Surgery and chemotherapy	NS	No case in bleomycin plus surgery arm (bleomycin only as reference) <sup>1</sup>	NS	= Very low <sup>1</sup>
Combinations	Surgery and radiotherapy	= Very low <sup>40</sup>	= Very low <sup>1,40</sup>	NS	↑ Very low <sup>1,40</sup>
	Radiotherapy and chemotherapy	↓ Very low <sup>41</sup>	= Very low <sup>1,41</sup>	NS	↑ Very low <sup>1,41</sup>
	Yes/no	= Very low <sup>40</sup>	= Very low <sup>40</sup>	NS	= Very low <sup>40</sup>
	(Ex-)smoker vs. smoker	↑ Very low <sup>43</sup>	$= \text{Very low}^{2,41,43}$	NS	$= Very low^{2,43,44,45}$
Smoking	Higher dose (pack years)	NS	NS	NS	NS
	Environmental exposure	NS	NS	NS	NS
	Cannabis	NS	NS	NS	NS

Explanation for categorisation of risk factors: ↑ increased risk; ↓ decreased risk; = no increased risk, inconsistent or not significant findings.

GvHD, Graft versus Host Disease; TBI, Total Body Irradiation; HSCT, Haematopoietic Stem Cell Transplantation; NS, No Study. \*Categorisation of pulmonary function parameters by publication in Table 1

# Table 3: Main reasons for downgrading the quality of evidence

# Representativeness uncertain:

- 13 studies (50%) did not report original cohort sizes from where populations at-risk were selected (selection and attrition biases).

# Imprecision and indirectness in performing PFT:

- Only 15 of 27 included studies (56%) used ERS/ATS recommendations on how to perform PFT.

# Imprecision and indirectness in reporting PFT results:

- Only 20 of 27 studies (74%) reported the source of reference values used to standardise the survivor results. 22 different sources of reference values were used overall, with up to 10 different sources of reference values in the same study.
- Only 2 of 27 studies (7%) used the reference values from the global lung initiative, which is established as the international standard.

# **Inconsistent reporting of PFT results:**

- 20 of 27 studies reported percentage of predicted values
- 5 of 27 studies reported z-scores
- 1 of 27 studies reported percentage of predicted values and z-scores
- 1 of 27 studies reported percentage of predicted and absolute values

**Inconsistent definitions of cut-off values** used to define normal values, obstruction, restriction, or diffusion capacity impairment

Abbreviations: ATS, American Thoracic Society; ERS, European Respiratory Society; PFS, pulmonary function testing

Table 4: Harmonised recommendations for surveillance of pulmonary dysfunction for childhood, adolescent, and young adult cancer survivors.

#### **General recommendations**

CAYA cancer survivors and their healthcare providers should be aware of the risk of reduced pulmonary function, and pay attention to symptoms (shortness of breath on exertion, chronic cough) after treatment with:

- Allogeneic haematopoietic stem cell transplantation (very low quality of evidence)
- Radiotherapy to fields exposing lung tissue, including TBI (very low to moderate quality of evidence)
- Surgery to the lung or chest wall (very low quality of evidence)

# (strong recommendation)

In at-risk\* CAYA cancer survivors it is recommended to:

- Get a yearly influenza vaccination and additional vaccinations based on local or national recommendations
- Consider vaccination against viral pathogens that cause pneumonias according to local or national guidelines

## For all CAYA cancer survivors it is recommended to:

- Avoid tobacco exposure, quit smoking, and/or reduce exposure to environmental smoke (strong recommendation, expert opinion)

Who needs surveillance for pulmonary dysfunction and what surveillance modality should be used?

Routine pulmonary function testing is not recommended for <u>asymptomatic</u> at-risk\* CAYA cancer survivors, due to lack of interventions to prevent the deterioration of asymptomatic pulmonary dysfunction (strong recommendation, lack of evidence, expert opinion)

\*Survivors treated with allogeneic haematopoietic stem cell transplantation (very low quality of evidence); radiotherapy to fields exposing lung tissue, including TBI (very low to moderate quality of evidence); and surgery to the lung or chest wall (very low quality of evidence)

Abbreviations: CAYA, childhood adolescent and young adult; TBI, total body irradiation

Table 5: Gaps in knowledge and future directions for research

## Current knowledge gaps

Risk factors for symptomatic and asymptomatic pulmonary dysfunction among CAYA cancer survivors, including therapeutic exposures, medical conditions, and environmental exposures.

- Treatment with
  - chemotherapeutic agents with reported pulmonary toxicity according to current LTFU guidelines, such as bleomycin, busulfan, carmustine, lomustine
  - chemotherapeutic agents without reported pulmonary toxicity according to current LTFU guidelines and without clear evidence, such as cyclophosphamide, methotrexate
  - targeted agents, such as tyrosine kinase inhibitors, checkpoint inhibitors, and monoclonal antibodies
  - immunotherapy, such as chimeric antigen receptor T-cell therapy
  - thoracic radiotherapy, such as proton versus photon therapy, and increasing radiation doses or volumes
  - thoracic surgery, such as thoracotomy and pneumonectomy
  - haematopoietic stem cell transplantation
  - combination of the above-mentioned treatment modalities
  - combination of bleomycin with additional oxygen (during anaesthesia)
- Impact of time from exposure on pulmonary function
- Impact of age at exposure on the risk of developing pulmonary dysfunction
- Impact of attained age at screening on outcome measures, such as PFT results, and clinical symptoms
- Impact of existing co-morbidities on pulmonary function, such as cardiac disease, impaired immune function, and neurological deficits
- Impact of genetic variants on pulmonary toxicity of cancer treatments
- Impact of acute treatment-related toxicities on pulmonary function, such as pulmonary infections, pulmonary GvHD
- Impact of inhaled substances, such as vaping, medicinal cannabis, alone or in combination with smoking cigarettes (during therapy and post-therapy)

## Detection of pulmonary dysfunction among CAYA cancer survivors

- Benefit of novel PFT, such as multiple-breath washout tests, exhaled nitric oxide, impulse oscillometry, and lung imaging (MRI), including acceptability, sensitivity, specificity, practical consequences, and costs
- Longitudinal course of pulmonary dysfunction after cancer treatments, including onset and progression, to determine intervals for PFT
- Effects of the cancer itself and cancer treatments on physiological processes, including lung growth, peak attained lung function, and functional decline with ageing
- Association of functional outcomes (from PFT detected by screening) with clinical symptoms (onset, type, and severity)
- Predictive value of serial PFT to identify individuals who will develop pulmonary dysfunction in the future and who will become symptomatic
- Predictive value of serial lung function tests with relation to termination of screening (normal or stable results)
- Cost-effectiveness of different screening frequencies and modalities
- Potential harms associated with excessive screening and false-positive findings

## Interventions to prevent, reverse, or slow the decline in pulmonary function

- Effect of variation in cancer treatments, such as radiotherapy, chemotherapy, or surgery on pulmonary dysfunction
- Effect of lifestyle and other preventive strategies on development or worsening of pulmonary dysfunction, such as lifestyle counselling and physical activity
- Effect of interventions, such as medical treatments and physiotherapy, to improve or reverse pulmonary dysfunction
- Benefit of optimal management of co-morbidities, such as cardiac dysfunction and chronic immunosuppression, on pulmonary dysfunction and pulmonary symptoms
- Effect of therapeutic targets used for other pulmonary diseases, such as antifibrotic drugs

# Factors to be considered in future studies assessing the risk of pulmonary dysfunction among CAYA cancer survivors

• Close collaboration between oncologists and pulmonologists; paediatric and adult experts.

#### Study design

- Need for sufficient numbers of CAYA cancer survivors undergoing PFT to maximise statistical power and allow stratifying analyses into sub-groups
- Collaboration between different study groups working with harmonised protocols
- Avoidance of selection or attrition bias among study cohorts, by testing independent of pulmonary symptoms; access to testing independent of socioeconomic factors etc
- Longitudinal investigations including baseline before starting treatment and serial assessment of pulmonary function and correlation with symptoms and other patientreported outcomes

## **Standardisation of PFT**

- Performance of PFT by trained personnel in centres with expertise / accredited centres
- Performance of PFT according to standardised protocols, such as ERS/ATS guidelines
- Interpretation of PFT results according to standardised protocols for quality control, such as ERS/ATS guidelines, and standardised reference values, stratified by age and sex, such as GLI
- Reporting PFT results as raw data and z-scores instead of binary cut-offs, such as normal or abnormal, restrictive, obstructive, or diffusion capacity impairment
- Measurement of different lung function parameters to better describe the nature of lung function impairment
- Using novel PFT to facilitate detection of pulmonary dysfunction

Abbreviations: ATS, American Thoracic Society; CAYA, childhood adolescent and young adult; ERS, European Respiratory Society; GvHD, Graft versus Host Disease; GLI, Global Lung Initiative; MRI, magnetic resonance imaging; LTFU, long-term follow-up; PFT, pulmonary function testing